Atıf İçin Kopyala
GÜR S., Kadowitz P. J., Hellstrom W. J. G.
EXPERT OPINION ON DRUG SAFETY, cilt.12, sa.1, ss.81-90, 2013 (SCI-Expanded)
-
Yayın Türü:
Makale / Derleme
-
Cilt numarası:
12
Sayı:
1
-
Basım Tarihi:
2013
-
Doi Numarası:
10.1517/14740338.2013.742885
-
Dergi Adı:
EXPERT OPINION ON DRUG SAFETY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.81-90
-
Anahtar Kelimeler:
5-alpha reductase enzyme, benign prostatic hyperplasia, dutasteride, finasteride, hair loss, human erectile function, BENIGN PROSTATIC HYPERPLASIA, URINARY-TRACT SYMPTOMS, QUALITY-OF-LIFE, 5-ALPHA-REDUCTASE INHIBITOR, COMBINATION THERAPY, TISSUE DISTRIBUTION, PENILE ERECTION, FINASTERIDE, MEN, DUTASTERIDE
-
Ankara Üniversitesi Adresli:
Evet
Özet
Introduction: Treatment with 5-alpha reductase inhibitors (5ARI) is commonly utilized for the treatment of benign prostatic hyperplasia (BPH). The true prevalence of sexual side effects with 5ARI treatment is currently unknown.